Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure

Journal of Cardiac Failure

Volumn 9, Issue 1, 2003, Pages 36-41

  Sueta, Carla A ^a,b   Massing, Mark W ^a,c   Chowdhury, Mridul ^a   Biggs, David P ^a   Simpson Jr , Ross J ^a,b  

^a Medical Review of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IL   (United States)

Author keywords

Coronary artery disease; Heart failure; Lipid lowering therapy; Quality of care

Indexed keywords

ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGE; AGED; AMBULATORY CARE; ANAMNESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; GEOGRAPHY; HEALTH CARE QUALITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MALE; MEDICAL RECORD; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 0037298509     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2003.5     Document Type: Article

References (23)

1. Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001;54:680-686.
2. Kannel WB. Epidemiology and prevention of cardiac failure: Framingham Study insights. Eur Heart J 1987; 8(Suppl F):23-26.
3. Remme WJ. Overview of the relationship between ischemia and congestive heart failure. Clin Cardiol 2000; 23:IV4-IV8.
4. Kannel WB. Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure. Cardiovasc Drugs Ther 1997; 11(Suppl 1):199-212.
5. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346.
6. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-254.
7. Sacks FM, Pfeffer MA, Moyer LA, Rouleau JL, Rutherford JD, Cole TG, et al, for Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1301-1307.
8. Segal R, Pitt B, Poole Wilson P, Sharma D, Bradstreet D, Ikeda LS on behalf of the ELITE II Investigators. Effects of HMG-COA reductase inhibitors (statins) in patients with heart failure (abstract). Eur J Heart Failure 2000; 2(Suppl 2):96.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
10. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
11. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). 2001. American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/failure/hf_index.htm.
12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
13. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. Am J Cardiol 1998;82:668-669.
14. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol 1997;29:139-146.
15. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith Jr SC, Alexander CM, Londhe A, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-1307.
16. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson Jr RJ. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001;87:646-649.
17. Simpson Jr RJ, Sueta CA, Boccuzzi SJ, Lulla A, Biggs D, Londhe A, et al. Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction. Am J Cardiol 1997;80(8B): 53H-56H.
18. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-873.
19. Aronow WS Han C. Frequency of congestive heart failure in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl treated with statins versus no lipid-lowering drugs: Am J Cardio 2002;90:1497-1499.
20. Grundy SM, Coleman JI, Rifling BM, and Keller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999;159:1670-1678.
21. Lai LL, Goblet M, and Belo C. Are patients with hyperlipidemia being treated? Investigation of cholesterol treatment practices in an HMO primary care setting. South Med J 2000;93:283-286.
22. Yarzebski J, Spencer F, Goldberg RJ, Lessard D, Gore JM. Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. Arch Intern Med 2001;161:1521-1528.
23. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279: 1458-1462.